ID
29527
Beschrijving
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Investigational Product Compliance
Trefwoorden
Versies (2)
- 04-03-18 04-03-18 -
- 05-04-18 05-04-18 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
5 april 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463
Investigational Product Compliance
- StudyEvent: ODM
Similar models
Investigational Product Compliance
- StudyEvent: ODM
C1321605 (UMLS CUI-2)
C0947323 (UMLS CUI [1,2])
C0545082 (UMLS CUI [1,3])
C0947323 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0332156 (UMLS CUI [1,2])
C0545082 (UMLS CUI [1,3])
C0332156 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0806020 (UMLS CUI [1,2])
C0180098 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])